Connection

William Creasman to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications William Creasman has written about Ovarian Neoplasms.
William Creasman
Connection Strength
2.795
Ovarian Neoplasms
  1. Hormone replacement therapy after cancers. Curr Opin Oncol. 2005 Sep; 17(5):493-9.
    View in: PubMed
    Score: 0.223
  2. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003 May; 188(5):1174-6.
    View in: PubMed
    Score: 0.190
  3. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5.
    View in: PubMed
    Score: 0.173
  4. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001 Jul; 82(1):7-10.
    View in: PubMed
    Score: 0.167
  5. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 1997 Aug; 66(2):171-8.
    View in: PubMed
    Score: 0.128
  6. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
    View in: PubMed
    Score: 0.120
  7. Ovarian cancer screening. J Clin Oncol. 1995 Mar; 13(3):783-93.
    View in: PubMed
    Score: 0.108
  8. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S122-7.
    View in: PubMed
    Score: 0.106
  9. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One. 2013; 8(3):e60185.
    View in: PubMed
    Score: 0.094
  10. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol. 1991 Dec; 78(6):1027-32.
    View in: PubMed
    Score: 0.086
  11. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991 Jul 15; 68(2):269-71.
    View in: PubMed
    Score: 0.084
  12. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
    View in: PubMed
    Score: 0.080
  13. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group Study). Gynecol Oncol. 1989 Dec; 35(3):378-82.
    View in: PubMed
    Score: 0.075
  14. Prognostic factors in relation to second-look laparotomy in ovarian cancer. Baillieres Clin Obstet Gynaecol. 1989 Mar; 3(1):183-90.
    View in: PubMed
    Score: 0.071
  15. Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg. 1988 Jan; 123(1):42-5.
    View in: PubMed
    Score: 0.066
  16. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol. 1987 May; 156(5):1153-8.
    View in: PubMed
    Score: 0.063
  17. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 1987 Jan; 26(1):11-8.
    View in: PubMed
    Score: 0.061
  18. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S161-92.
    View in: PubMed
    Score: 0.061
  19. Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol. 1985 Dec 15; 153(8):828-34.
    View in: PubMed
    Score: 0.057
  20. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1985 Jun 15; 152(4):418-23.
    View in: PubMed
    Score: 0.055
  21. A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies. Am J Obstet Gynecol. 1984 Dec 15; 150(8):927-31.
    View in: PubMed
    Score: 0.053
  22. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984 Jun; 7(3):257-60.
    View in: PubMed
    Score: 0.051
  23. Carcinoma of the ovary. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:135-66.
    View in: PubMed
    Score: 0.049
  24. Immune complexes in ovarian cancer. Gynecol Oncol. 1982 Apr; 13(2):203-12.
    View in: PubMed
    Score: 0.044
  25. Stage I borderline ovarian tumors. Obstet Gynecol. 1982 Jan; 59(1):93-6.
    View in: PubMed
    Score: 0.043
  26. Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecol Oncol. 1981 Dec; 12(3):319-27.
    View in: PubMed
    Score: 0.043
  27. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol. 1980 Sep 15; 138(2):139-45.
    View in: PubMed
    Score: 0.040
  28. Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979 Feb; 63(2):319-23.
    View in: PubMed
    Score: 0.035
  29. Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma. Am J Obstet Gynecol. 1978 Nov 01; 132(5):555-60.
    View in: PubMed
    Score: 0.035
  30. Retroperitoneal metastatic spread of ovarian cancer. Gynecol Oncol. 1978 Oct; 6(5):447-50.
    View in: PubMed
    Score: 0.035
  31. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol. 1996 Jul; 62(1):4-6.
    View in: PubMed
    Score: 0.030
  32. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
    View in: PubMed
    Score: 0.028
  33. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr; 170(4):974-9; discussion 979-80.
    View in: PubMed
    Score: 0.025
  34. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993 Jan 15; 71(2 Suppl):606-14.
    View in: PubMed
    Score: 0.023
  35. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992 Jan; 166(1 Pt 1):50-3.
    View in: PubMed
    Score: 0.022
  36. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15; 68(8):1758-63.
    View in: PubMed
    Score: 0.021
  37. Screening in ovarian cancer. Am J Obstet Gynecol. 1991 Jul; 165(1):7-10.
    View in: PubMed
    Score: 0.021
  38. Carcinoma of the ovary associated with pregnancy. Obstet Gynecol. 1971 Jul; 38(1):111-6.
    View in: PubMed
    Score: 0.021
  39. New gynecologic cancer staging. Obstet Gynecol. 1990 Feb; 75(2):287-8.
    View in: PubMed
    Score: 0.019
  40. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 01; 57(9):1725-30.
    View in: PubMed
    Score: 0.015
  41. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer. 1985 Jul 15; 56(2):243-8.
    View in: PubMed
    Score: 0.014
  42. Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol. 1983 Aug; 16(1):6-14.
    View in: PubMed
    Score: 0.012
  43. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol. 1983 Jun; 6(3):273-5.
    View in: PubMed
    Score: 0.012
  44. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol. 1981 Dec 15; 141(8):921-9.
    View in: PubMed
    Score: 0.011
  45. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2089-92.
    View in: PubMed
    Score: 0.009
  46. Unreliability of urinary cytology in detecting gynecologic malignancy. Cancer. 1972 Jul; 30(1):148-9.
    View in: PubMed
    Score: 0.006
  47. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol. 1971 Jul 15; 110(6):773-81.
    View in: PubMed
    Score: 0.005
  48. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 1990 Feb; 75(2):249-54.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.